BPS3012 Chap.6 Epigenetic Drug Discovery
Epigenetic Drug Discovery
Epigenetic Drug Discovery examines how chromatin state regulates access to genetic information without changing DNA sequence.
It distinguishes writers, erasers and readers, uses bromodomain inhibition to show how mark recognition becomes druggable, and separates biochemical selectivity from genomic and cellular consequences.
Chromatin regulation changes how readily cellular machinery can access genes without altering the underlying DNA sequence.
Writers add chemical marks, erasers remove them and readers recognise marked states to recruit other functions. This vocabulary is useful only when connected to consequence: a changed mark or reader interaction can alter transcriptional programmes, cell identity and disease behaviour.
Do not describe epigenetics as a simple on/off switch; effects depend on genomic location, interacting proteins and cellular context.
Bromodomains illustrate how recognition can become druggable. These domains bind acetylated lysine marks, so a small molecule that competes for the binding pocket can interrupt recruitment of a reader protein.
The causal chain is binding-site occupancy → altered chromatin association → changed transcription → cellular phenotype. Every arrow needs evidence. Potent biochemical binding does not prove displacement across the relevant genome, and a transcriptional change does not by itself establish that the intended pathway caused the phenotype.
Selectivity operates at several levels.
A compound may prefer one domain in a biochemical assay but show different behaviour in cells because of concentration, protein abundance, chromatin context or off-target interactions. Genome-wide measurements can reveal where occupancy or expression changes, while functional experiments test whether those changes matter. Rescue, perturbation or converging methods can strengthen causal interpretation.
The aim is not to collect the largest dataset; it is to connect molecular recognition to a reproducible disease-relevant consequence.
For revision, build a table with regulator class, molecular action, immediate chromatin effect, downstream readout and principal uncertainty.
When evaluating an epigenetic drug, state the disease rationale, identify the writer, eraser or reader involved, explain the intervention and specify evidence at biochemical, genomic and cellular levels. Finish with context and safety: broad transcriptional effects may create both therapeutic reach and unintended consequences.
A strong conclusion recommends the strategy only for the biological setting in which target engagement and functional dependence have both been demonstrated.
What this chapter covers
- 01
Chromatin state and gene expression
- 02
Epigenetic writers, erasers and readers
- 03
Differentiation and disease context
- 04
Bromodomain recognition of acetyl marks
- 05
Reader inhibition and transcriptional programmes
- 06
Biochemical, genomic and cellular selectivity
- 07
Association, mechanism and therapeutic window
Worked example · free
Explain bromodomain inhibition precisely
- +1Identify the bromodomain as a reader of an acetylated mark.
- +1Explain inhibitor binding to the recognition pocket.
- +1Connect blocked recognition to altered transcriptional recruitment.
- +1Link the changed programme to a disease-relevant phenotype.
- +1State the need to monitor broad transcriptional effects and normal cells.
Key terms
- Epigenetic regulation
- Control of gene access and expression without changing the underlying DNA sequence.
- Epigenetic writer
- An enzyme that adds a regulatory mark to DNA, histones or associated molecules.
- Epigenetic eraser
- An enzyme that removes a regulatory mark.
- Epigenetic reader
- A protein that recognises a regulatory mark and recruits downstream machinery.
- Bromodomain
- A protein domain that recognises acetylated lysine and can help organise transcriptional programmes.
Epigenetic Drug Discovery FAQ
Do epigenetic drugs edit DNA?
Not by default. They alter proteins that write, remove or read regulatory states, changing access and expression while leaving the DNA sequence unchanged unless a separate editing technology is involved. Explain the intervention through a causal chain: regulator engagement changes a chromatin interaction or mark, which alters a transcriptional programme and may change phenotype. Each link needs its own evidence.
A broad expression response does not prove that every downstream effect is intended or therapeutically selective.
Why can bromodomain inhibition change many genes?
One reader can participate at many regulatory regions. Strong biochemical preference for one protein does not guarantee narrow genomic or cellular consequences, so expression and phenotype must be profiled. Selectivity can differ between binding assays, chromatin occupancy and whole-cell response because abundance and context change.
Use target-engagement, genomic and functional measurements together, supported by controls or orthogonal perturbations. Normal-cell comparisons are also needed to judge whether a disease-relevant dependency offers a practical therapeutic window.
What establishes a causal epigenetic mechanism?
Intervene on the proposed regulator, confirm target engagement and the expected molecular change, show that the disease-relevant phenotype follows, and use rescue or orthogonal evidence where possible. Arrange the evidence as a chain rather than a collection of correlations.
If occupancy changes but the expected transcriptional programme does not, or the phenotype changes without the proposed molecular event, the mechanism needs revision. Normal-cell comparisons help determine whether the dependency can support a therapeutic window.
Assessment move
Map each target as writer, eraser or reader, then trace mark, chromatin interaction, expression programme and phenotype. Practise distinguishing association from causal intervention and biochemical selectivity from broader genomic effects. Always close with the evidence needed for a therapeutic window.
